Pancreatic cancer: New hopes after first line treatment.
Pancreatic cancer is the fourth leading cause of cancer-related death worldwide. Extensive research has yielded advances in first-line treatment strategies, but there is no standardized second-line therapy. In this review, we examine the literature trying to establish a possible therapeutic algorithm.
Francesca Aroldi, Paola Bertocchi, Alberto Zaniboni, Department of Medical Oncology, Poliambulanza Foundation, 25124 Brescia, Italy.
Francesca
F
Aroldi
Francesca Aroldi, Paola Bertocchi, Alberto Zaniboni, Department of Medical Oncology, Poliambulanza Foundation, 25124 Brescia, Italy.
Paola
P
Bertocchi
Francesca Aroldi, Paola Bertocchi, Alberto Zaniboni, Department of Medical Oncology, Poliambulanza Foundation, 25124 Brescia, Italy.
Giordano
G
Savelli
Francesca Aroldi, Paola Bertocchi, Alberto Zaniboni, Department of Medical Oncology, Poliambulanza Foundation, 25124 Brescia, Italy.
Edoardo
E
Rosso
Francesca Aroldi, Paola Bertocchi, Alberto Zaniboni, Department of Medical Oncology, Poliambulanza Foundation, 25124 Brescia, Italy.
Alberto
A
Zaniboni
Algorithm; Nab-paclitaxel; Nal-iri; Pancreatic cancer; Second line
Anticancer Res. 2010 Jul;30(7):2905-9
20683031
Onkologie. 2013;36(12):763-5
24356569
J Clin Oncol. 2013 Jan 1;31(1):23-9
23213101
Cancer Chemother Pharmacol. 2009 May;63(6):1141-5
18839175
Br J Cancer. 2006 Mar 27;94(6):785-91
16508631
Eur J Cancer. 2014 Jul;50(11):1909-15
24857345
Invest New Drugs. 2012 Jun;30(3):1216-23
21594619
Cancer Invest. 2005;23(1):9-12
15779862
Br J Cancer. 2003 Apr 22;88(8):1180-4
12698181
Am J Clin Oncol. 2013 Apr;36(2):151-6
22307213
N Engl J Med. 2013 Oct 31;369(18):1691-703
24131140
Br J Cancer. 2015 Sep 29;113(7):989-95
26372701
J Clin Oncol. 2016 Nov 10;34(32):3914-3920
27621395
Oncology. 2006;71(3-4):159-63
17646699
Exp Hematol Oncol. 2015 Oct 07;4:29
26451276
Oncology. 2009;76(4):270-4
19258727
J Gastrointest Oncol. 2015 Oct;6(5):511-5
26487945
N Engl J Med. 2011 May 12;364(19):1817-25
21561347
Br J Cancer. 2013 Aug 20;109(4):920-5
23880820
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29
25559415
J Chemother. 2008 Aug;20(4):509-12
18676234
J Clin Oncol. 2015 Dec 1;33(34):4039-47
26351344
Lancet. 2016 Feb 6;387(10018):545-557
26615328
Cancer Invest. 2008 Feb;26(1):47-52
18181045
BMC Cancer. 2016 Jan 15;16:21
26772812
Cancer Chemother Pharmacol. 2010 Nov;66(6):1051-7
20130876
World J Gastroenterol. 2016 Jan 14;22(2):748-63
26811622
J Clin Oncol. 2014 Aug 10;32(23):2423-9
24982456
J Gastrointest Cancer. 2015 Sep;46(3):201-11
25972062
Br J Cancer. 2006 Feb 27;94(4):481-5
16434988
J Clin Oncol. 2015 Jan 20;33(3):244-50
25366685
Am J Clin Oncol. 2011 Feb;34(1):70-5
20458210
Eur J Cancer. 2011 Jul;47(11):1676-81
21565490
Clin Cancer Res. 2016 Jan 1;22(1):61-8
26251290
Eur J Cancer. 2013 Nov;49(17):3609-15
23899530
Clin Ther. 2015 Jun 01;37(6):1301-16
25907619
Rev Recent Clin Trials. 2015;10(2):142-5
25881637
J Clin Oncol. 1997 Jun;15(6):2403-13
9196156
Anticancer Drugs. 2000 Sep;11(8):635-8
11081455
Cancer Chemother Pharmacol. 2012 Jun;69(6):1641-5
22576338
Invest New Drugs. 2012 Jun;30(3):1203-7
21526355